We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.185 | 0.65% | 28.77 | 28.63 | 28.825 | 28.945 | 28.54 | 28.605 | 59,387 | 22:50:04 |
By Ed Frankl
Bayer AG won a fourth case in the U.S. over claims that its Roundup weedkiller causes cancer, the company said late Friday.
A jury in Jackson County, Ore., found that the Roundup weedkiller didn't cause a man's cancer, according to the German pharmaceutical and agro-chemicals company.
It is the fourth case in a row that Bayer has won in less than a year, with the company dealing with a wave of claims since it took over Monsanto Co., the product's original owner, in 2018.
"The jury's conclusions are consistent with the assessments of expert regulators worldwide as well as the overwhelming evidence from four decades of scientific studies concluding that Roundup can be used safely and is not carcinogenic," Bayer said in a statement.
Separately, however, a U.S. federal appeals court on Friday ordered the Environmental Protection Agency to review its assessment that glyphosate, the active ingredient in Roundup, isn't harmful.
In a 3-0 decision, the Ninth Circuit Court of Appeals said the EPA hadn't adequately considered whether glyphosate causes cancer.
The previous EPA assessment is considered one of Bayer's arguments before the U.S. Supreme Court, which is expected to decide whether to review the company's award of $25 million in damages to Edwin Hardeman, who said his cancer was caused by the weedkiller.
Herbert Rude contributed to this article.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
June 20, 2022 02:00 ET (06:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions